Beam Therapeutics (NASDAQ:BEAM) Stock Price Breaks Below 50-Day Moving Average – Here’s What Happened

Beam Therapeutics Inc. (NASDAQ:BEAM)’s share price passed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $25.45 and traded as low as $23.60. Beam Therapeutics shares last traded at $25.15, with a volume of 3,115,247 shares.

Key Headlines Impacting Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Beam said its BEACON Phase 1/2 trial met its primary efficacy endpoint: patients were free of severe vaso-occlusive crises for at least 12 consecutive months. The study also met its primary safety and all secondary endpoints, including freedom from hospitalization for severe crises. Beam Therapeutics BEACON trial announcement
• Positive Sentiment: The results support Beam’s plan to submit a U.S. biologics license application for risto-cel as early as year-end 2026. If approved, the base-edited therapy could compete with existing sickle cell treatments Casgevy and Lyfgenia. Beam prepares FDA filing after pivotal success
• Positive Sentiment: HC Wainwright maintained its Buy rating and made modestly less-negative earnings estimates across several future periods, offering a secondary positive signal. These estimates were issued before the trial announcement. Beam Therapeutics analyst estimates
• Negative Sentiment: BEAM shares declined even as the trial news emerged. The supplied coverage noted the disconnect but did not identify a specific reason for the market’s reaction, so investors may be weighing the results against expectations and the remaining regulatory and commercialization steps. Beam shares fall despite trial win

Analyst Upgrades and Downgrades

BEAM has been the subject of several research reports. HC Wainwright reiterated a “buy” rating on shares of Beam Therapeutics in a research note on Tuesday, October 27th. Wall Street Zen lowered shares of Beam Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 31st. Canaccord Genuity Group decreased their price target on Beam Therapeutics from $79.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a report on Thursday, October 15th. Finally, Guggenheim lowered their target price on Beam Therapeutics from $55.00 to $51.00 and set a “buy” rating for the company in a research note on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Beam Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.36.

Beam Therapeutics Stock Down 6.9%

The company has a debt-to-equity ratio of 0.11, a current ratio of 13.01 and a quick ratio of 13.00. The firm has a 50-day moving average price of $25.45 and a two-hundred day moving average price of $27.96. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -24.18 and a beta of 2.23.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.11). The business had revenue of $0.31 million during the quarter, compared to analyst estimates of $8.75 million. Beam Therapeutics had a negative net margin of 73.04% and a negative return on equity of 32.76%. The firm’s quarterly revenue was down 96.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.10) earnings per share. As a group, sell-side analysts anticipate that Beam Therapeutics Inc. will post -4.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Beam Therapeutics

In related news, CEO John Evans sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the transaction, the chief executive officer directly owned 1,047,205 shares of the company’s stock, valued at approximately $24,682,621.85. The trade was a 2.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in Beam Therapeutics in the second quarter valued at about $308,796,000. ARCH Venture Management LLC acquired a new stake in shares of Beam Therapeutics during the 2nd quarter valued at $155,771,929. Dimensional Fund Advisors LP boosted its stake in shares of Beam Therapeutics by 10.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,154,575 shares of the company’s stock valued at $51,327,000 after purchasing an additional 206,696 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Beam Therapeutics during the 1st quarter worth approximately $34,467,000. Finally, Bank of America Corp DE bought a new stake in shares of Beam Therapeutics in the second quarter worth $24,733,000. 99.68% of the stock is owned by institutional investors.

About Beam Therapeutics

Beam Therapeutics is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development. The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body.